Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
H. Michael Shepard, William P. Harris, Sergei Tjulandin, Eduard M. Pshevlotsky, Craig Devoe, Oleg Gladkov, Ronald L. Korn, Randall F. Holcombe, Natarajan Raghunand, J. Thaddeus Beck, Boris A. Berdov, Ping Jiang, Stephanie Ann Wagner, Samuel S. Dychter, Sunil R. Hingorani
Publikováno v:
Clin Cancer Res
Purpose: This phase Ib study evaluated the safety and tolerability of PEGylated human recombinant hyaluronidase (PEGPH20) in combination with gemcitabine (Gem), and established a phase II dose for patients with untreated stage IV metastatic pancreati
Autor:
Safi Shahda, Hui-Ling Zhen, Daniel D. Von Hoff, Albert Assad, A. Eli Gabayan, J. Thaddeus Beck, Steven J. Cohen, Gregory L. Beatty, Nikhil Uppal, Ross C. Donehower, Julie Switzky
Publikováno v:
Journal of Clinical Oncology. 35:362-362
362 Background: JAK-STAT activity has been associated with malignant cell proliferation and production of proinflammatory cytokines involved in cancer progression. INCB039110 is a potent and selective inhibitor of JAK1. Methods: This was a 2-part pha
Autor:
Todd M. Bauer, J. R. Infante, Mark J. O'Connor, J. Thaddeus Beck, Howard A. Burris, Philip J. Jewsbury, Andrew J. Pierce, Carl Cook, Kathleen N. Moore, Carol Greenlees, David R. Spigel, Suzanne F. Jones, Melissa Lynne Johnson, Lowell L. Hart, Ganesh Mugundu
Publikováno v:
Cancer Research. 76:CT013-CT013
Many cancers are associated with DNA repair and cell cycle mutations that result in G1/S checkpoint deficiencies and higher levels of endogenous damage and replication stress. This can lead to dependency on WEE1 kinase, which provides an important G2
Autor:
Fabrice Andre, J. Thaddeus Beck, José Baselga, Valerie Donnet, Miguel Martín, Giampaolo Tortora, Lars Blumenstein, Giuseppe Curigliano, Laure Charbonnier, Nicola Fazio, C. Wilke
Publikováno v:
Cancer Research. 76:CT061-CT061
Background: PIK3CA (encoding phosphatidylinositol 3-kinase [PI3K] p110α) is frequently altered in cancer, resulting in PI3K/mammalian target of rapamycin (mTOR) pathway activation, and contributing to targeted therapy resistance and disease progress
Autor:
Alain C. Mita, Albert C. Lockhart, Kevin M. Chin, James L. Gulley, Anja von Heydebreck, J. Thaddeus Beck, Erika Hamilton, Shubham Pant, Michael S. Gordon, Mary L. Disis, Manish R. Patel, Karen Kelly, Matthew H. Taylor, Jean-Marie Cuillerot, Jorge Chaves, Glen J. Weiss
Publikováno v:
Journal of Clinical Oncology. 34:5533-5533
5533Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report safety and clinical activity of avelumab in patients (pts) with recurrent/refractory ovarian cancer (OC; NCT01772004). Met